Common Stock and Stock-Based Incentive Compensation Plans (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Share-Based Payment Arrangement [Abstract] |
|
Schedule of Common Shares Outstanding |
Shares of common stock outstanding were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended |
|
December 31, 2022 |
|
December 25, 2021 |
|
December 26, 2020 |
|
(In millions) |
Balance, beginning of period |
1,207 |
|
|
1,211 |
|
|
1,170 |
|
Common stock issued in the acquisition of Xilinx |
429 |
|
|
— |
|
|
— |
|
Common stock issued under employee equity plans |
17 |
|
|
12 |
|
|
14 |
|
Repurchases of common stock |
(36) |
|
|
(17) |
|
|
— |
|
Common stock repurchases for tax withholding on equity awards |
(5) |
|
|
(2) |
|
|
(1) |
|
|
|
|
|
|
|
Issuance of common stock to settle convertible debt |
— |
|
|
3 |
|
|
28 |
|
|
|
|
|
|
|
Balance, end of period |
1,612 |
|
|
1,207 |
|
|
1,211 |
|
|
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs |
Stock-based compensation expense was allocated in the consolidated statements of operations as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended |
|
December 31, 2022 |
|
December 25, 2021 |
|
December 26, 2020 |
|
(In millions) |
Cost of sales |
$ |
29 |
|
|
$ |
5 |
|
|
$ |
6 |
|
Research and development |
697 |
|
|
246 |
|
|
173 |
|
Marketing, general, and administrative |
355 |
|
|
128 |
|
|
95 |
|
Total stock-based compensation expense before income taxes |
1,081 |
|
|
379 |
|
|
274 |
|
Income tax benefit |
(179) |
|
|
(58) |
|
|
(42) |
|
Total stock-based compensation expense, net of income taxes |
$ |
902 |
|
|
$ |
321 |
|
|
$ |
232 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions |
The weighted-average estimated fair value of employee stock options granted during 2022, 2021 and 2020 was $44.35, $46.07 and $38.49 per share, respectively, using the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
December 25, 2021 |
|
December 26, 2020 |
Expected volatility |
51.28 |
% |
|
51.77 |
% |
|
57.87 |
% |
Risk-free interest rate |
3.00 |
% |
|
0.69 |
% |
|
0.18 |
% |
Expected dividends |
— |
% |
|
— |
% |
|
— |
% |
Expected life (in years) |
4.75 |
|
4.55 |
|
4.30 |
The weighted-average grant date fair values of PRSUs granted during 2022, 2021 and 2020 were $121.12, $153.89 and $122.95, respectively, using the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
December 25, 2021 |
|
December 26, 2020 |
Expected volatility |
50.65% - 53.51% |
|
57.75 |
% |
|
55.74% - 60.10% |
Risk-free interest rate |
1.14% - 3.17% |
|
0.43 |
% |
|
0.14% - 1.41% |
Expected dividends |
— |
% |
|
— |
% |
|
— |
% |
Expected term (in years) |
2.07 - 3.07 |
|
3.00 |
|
2.48 - 3.00 |
|
Schedule of Share-based Compensation, Stock Options, Activity |
The following table summarizes stock option activity and related information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding Number of Shares |
|
Weighted- Average Exercise Price |
|
Aggregate Intrinsic Value |
|
Weighted-Average Remaining Contractual Life (in years) |
|
(In millions, except share price) |
|
|
Balance as of December 25, 2021 |
5 |
|
|
$ |
23.98 |
|
|
|
|
|
Granted |
1 |
|
|
$ |
95.54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised |
(2) |
|
|
$ |
4.27 |
|
|
|
|
|
Balance as of December 31, 2022 |
4 |
|
|
$ |
42.35 |
|
|
$ |
130 |
|
|
3.17 |
Exercisable December 31, 2022 |
3 |
|
|
$ |
25.67 |
|
|
$ |
130 |
|
|
2.27 |
|
Schedule of Share-based Compensation, Restricted Stock Units, Activity |
The following table summarizes time-based RSU activity and related information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares |
|
Weighted- Average Grant Date Fair Value |
|
Aggregate Intrinsic Value |
|
Weighted-Average Remaining Contractual Life (in years) |
|
(In millions except share price) |
|
|
Unvested shares as of December 25, 2021 |
10 |
|
|
$ |
79.03 |
|
|
|
|
|
Assumed with acquisition of Xilinx |
12 |
|
|
$ |
103.35 |
|
|
|
|
|
Granted |
17 |
|
|
$ |
92.92 |
|
|
|
|
|
Forfeited |
(2) |
|
|
$ |
98.06 |
|
|
|
|
|
Vested |
(9) |
|
|
$ |
86.27 |
|
|
|
|
|
Unvested shares as of December 31, 2022 |
28 |
|
|
$ |
95.49 |
|
|
$ |
1,810 |
|
|
1.67 |
|
Schedule of Nonvested Performance-based Units Activity |
The following table summarizes PRSU activity and related information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares |
|
Weighted-Average Grant Date Fair Value |
|
Aggregate Intrinsic Value |
|
Weighted-Average Remaining Contractual Life (in years) |
|
(In millions except share price) |
|
|
Unvested shares as of December 25, 2021 |
2 |
|
|
$ |
78.59 |
|
|
|
|
|
Granted |
1 |
|
|
$ |
121.12 |
|
|
|
|
|
Forfeited |
— |
|
|
$ |
— |
|
|
|
|
|
Vested |
(1) |
|
|
$ |
51.77 |
|
|
|
|
|
Unvested shares as of December 31, 2022 |
2 |
|
|
$ |
110.31 |
|
|
$ |
118 |
|
|
1.76 |
|
Schedule of ESPP |
The weighted-average grant date fair value for the ESPP during 2022, 2021 and 2020 was $24.71, $27.27 and $20.97 per share, respectively, using the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
December 25, 2021 |
|
December 28, 2020 |
|
|
|
|
Expected volatility |
58.15% - 63.76% |
|
36.90% - 39.39% |
|
55.16% - 66.53% |
|
|
|
|
Risk-free interest rate |
1.43% - 4.52% |
|
0.04% - 0.07% |
|
0.11% - 0.15% |
|
|
|
|
Expected dividends |
— |
% |
|
— |
% |
|
— |
% |
|
|
|
|
Expected term (in years) |
0.50 |
|
0.50 |
|
0.50 |
|
|
|
|
|